Reports Q3 revenue $15.08M, consensus $15.25M. “We made significant progress at Ocular Therapeutix in the third quarter,” said Antony Mattessich, President and CEO. “In a critical step forward for our clinical program, we initiated the first pivotal trial evaluating AXPAXLI for the treatment of wet AMD and subsequently have received FDA agreement with our overall clinical plan under a Special Protocol Assessment. We are thrilled to have agreement with the FDA regarding our trial design and are very excited to continue moving forward toward our goal of bringing a potentially transformative new treatment to wet AMD patients coping with vision loss.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
- Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
- Ocular Therapeutix Inc (OCUL) Q3 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- Ocular Therapeutix receives FDA agreement under SPA for trial of OTX-TKI
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue